Xenoport Inc (NASDAQ:XNPT)

Data as of Jan 30
 -0.57 / -6.40%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. The company's first product gabapentin enacarbil which is known as Horizant in United States and Regnite in Japan, is developed for the treatment of moderate-to-severe primary restless legs syndrome in adults. The XenoPort holds all other world-wide rights and has co-promotion and certain development rights to gabapentin enacarbil in the United States. The company's pipeline of products candidates includes potential treatments for patients with Postherpetic Neuralgia, Spasticity and Parkinson's disease. XenoPort was founded by Ronald W. Barrett, William J. Dower and Mark A. Gallop on May 19, 1999 and is headquartered in Santa Clara, CA.

Contact Information

XenoPort, Inc.
3410 Central Expressway
Santa Clara California 95051
P:(408) 616-7200
Investor Relations:
(408) 616-7220



Individual stakeholders8.71%
Other institutional56.70%
Mutual fund holders35.76%

Top Executives

Ronald W. BarrettChief Executive Officer & Director
Vincent J. AngottiChief Operating Officer & Executive Vice President
William G. HarrisChief Financial Officer & Senior Vice President
Kenneth C. CundyChief Scientific Officer
Richard K. KimChief Medical Officer & SVP-Clinical Development

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer.

Morningstar: © 2015 Morningstar, Inc. All Rights Reserved.

Factset: FactSet Research Systems Inc. 2015. All rights reserved.

Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved.

Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor’s Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2015 and/or its affiliates.